November 24, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Nippon Shinyaku, Janssen Pharmaceutical, Grunenthal to Collaborate in Development of Oral Analgesic in Japan
 

Tokyo, Feb 22, 2005 (JCN) - Nippon Shinyaku has announced that it has mutually agreed with Janssen Pharmaceutical and Grunenthal GmbH to collaborate in the development of Tramadol hydrochloride, an oral analgesic developed by Grunenthal, in Japan. Launched in 1981, Tramadol hydrochloride has been distributed in over 100 countries worldwide.

In Japan, Nippon Shinyaku has been conducting clinical development in the field of cancer pain since 1996. Under this alliance, Janssen will carry out further development in the field of non-cancer pain. In either field, Nippon Shinyaku and Janssen will jointly file a new drug application and market it separately under their own trade names.

By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Nippon Shinyaku News  
  Nippon Shinyaku Launches Oligo RNA for Research Reagent  (July 13, 2007)
  Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the Treatment of Overactive Bladder  (Jan 25, 2007)
  Nippon Shinyaku and Roche Terminate NS-220 License Agreement  (Dec 18, 2006)
  Bayer Yakuhin Files Anti-cancer Drug Nexavar(R) for the Treatment of Advanced Renal Cell Carcinoma  (June 29, 2006)
  Bayer Yakuhin to Transfer Baynas Marketing Rights to Nippon Shinyaku  (Apr 24, 2006)
  Nippon Shinyaku, INNOVIVE Pharmaceuticals Conclude Licensing Agreement for NS-187, Drug Candidate for Chronic Myelogenous Leukemia  (Jan 6, 2006)
  Nippon Shinyaku Begins Shipping New Ethical Drug Lodocoat Ointment 0.9%  (Aug 23, 2005)
  Nippon Shinyaku Now Distributes AMNOLAKE Tablet, Agent for Acute Promyelocytic Leukemia  (June 14, 2005)
  Nippon Shinyaku, Jeil-Kirin Pharmaceutical Conclude Licensing Agreement for TRISENOX Injection  (May 23, 2005)
  Hisamitsu Pharmaceutical, Nippon Shinyaku Conclude Joint Development Agreement for HFT-290 Cancer Pain Palliative Care Agent  (Apr 8, 2005)



 Recent  Drugs & OTC News   
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)

More Drugs & OTC news...

 Recent  Drugs & OTC News   
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)